| scholarly article | Q13442814 |
| P2093 | author name string | Roslyn B Mannon | |
| Michael E Seifert | |||
| P2860 | cites work | A Randomized Trial of Intensive versus Standard Blood-Pressure Control | Q27231406 |
| Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance | Q29615569 | ||
| Survival Analysis in the Presence of Competing Risks: The Example of Waitlisted Kidney Transplant Candidates. | Q30251974 | ||
| Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality | Q30427104 | ||
| Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood | Q33480997 | ||
| Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study | Q33521348 | ||
| Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. | Q33791650 | ||
| Urinary-cell mRNA profile and acute cellular rejection in kidney allografts | Q34037420 | ||
| Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. | Q34181871 | ||
| Chronic rejection | Q34241121 | ||
| Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation | Q34455315 | ||
| Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study | Q34483895 | ||
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 | ||
| From dialysis to transplantation: a 5-year longitudinal study on self-reported quality of life | Q34649498 | ||
| Quantifying renal allograft loss following early antibody-mediated rejection. | Q35007419 | ||
| Racial and ethnic disparities in pediatric renal allograft survival in the United States | Q35132480 | ||
| The mortality risk with graft function has decreased among children receiving a first kidney transplant in the United States | Q35132495 | ||
| Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies | Q35228551 | ||
| Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? | Q35639150 | ||
| Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts | Q35790552 | ||
| Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection | Q35922715 | ||
| Variation in Dialysis Facility Referral for Kidney Transplantation Among Patients With End-Stage Renal Disease in Georgia | Q36064120 | ||
| Chronic allograft nephropathy | Q36094077 | ||
| Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial | Q36179462 | ||
| Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation | Q36281955 | ||
| Angiotensin II blockade in kidney transplant recipients | Q36574775 | ||
| SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology. | Q36937329 | ||
| Urine proteomics to detect biomarkers for chronic allograft dysfunction. | Q37086665 | ||
| Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study | Q37097454 | ||
| Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond | Q37325196 | ||
| Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. | Q37416887 | ||
| Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function | Q37535280 | ||
| The pathogenesis and treatment of chronic allograft nephropathy | Q37563986 | ||
| Significance and management of proteinuria in kidney transplant recipients | Q37612655 | ||
| Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. | Q37648959 | ||
| Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation | Q38008362 | ||
| Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation | Q38069292 | ||
| Through a glass darkly: seeking clarity in preventing late kidney transplant failure | Q38237365 | ||
| Kidney transplantation in children | Q38237543 | ||
| Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches | Q38353255 | ||
| Blood Vessels in Allotransplantation | Q38390676 | ||
| Health-related quality of life and long-term survival and graft failure in kidney transplantation: a 12-year follow-up study. | Q39478381 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation | Q40320279 | ||
| Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts | Q40429580 | ||
| Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function | Q40682324 | ||
| Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial | Q40998457 | ||
| Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. | Q42111937 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study | Q42268606 | ||
| A peripheral blood diagnostic test for acute rejection in renal transplantation. | Q42848519 | ||
| Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. | Q43172317 | ||
| Strict blood-pressure control and progression of renal failure in children | Q43257210 | ||
| Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss | Q43817587 | ||
| Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 | ||
| Increased urinary CCL2: Cr ratio at 6 months is associated with late renal allograft loss | Q44008607 | ||
| Mortality after kidney transplant failure: the impact of non-immunologic factors | Q44021232 | ||
| Survival after dialysis initiation: a comparison of transplant patients after graft loss versus nontransplant patients. | Q44111851 | ||
| Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. | Q44260404 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. | Q44792449 | ||
| Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation | Q45407225 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Identifying specific causes of kidney allograft loss. | Q45810388 | ||
| Health-related quality of life and clinical outcomes in kidney transplant recipients. | Q45921465 | ||
| Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. | Q45964495 | ||
| Kidney allograft survival after acute rejection, the value of follow-up biopsies | Q46211382 | ||
| Costimulation blockade with belatacept in renal transplantation | Q46569880 | ||
| Prevention of chronic allograft nephropathy with vitamin D. | Q46702673 | ||
| Long-term survival in renal transplant recipients with graft function | Q46703295 | ||
| Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining | Q46945380 | ||
| Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials | Q48076383 | ||
| Death after graft loss: an important late study endpoint in kidney transplantation. | Q50711901 | ||
| Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection. | Q50910367 | ||
| Kidney allograft function and histology in recipients dying with a functioning graft. | Q51080659 | ||
| A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. | Q51432032 | ||
| Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 | ||
| The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. | Q52962136 | ||
| Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. | Q53459320 | ||
| Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. | Q53521493 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics | Q57506046 | ||
| Elevated Urinary CCL2 | Q58194212 | ||
| Differences in quality of life across renal replacement therapies: A meta-analytic comparison | Q60677879 | ||
| Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') | Q79921621 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys | Q83387311 | ||
| Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 | ||
| De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure | Q84752864 | ||
| Improving long-term outcomes for transplant patients: making the case for long-term disease-specific and multidisciplinary research | Q85013471 | ||
| Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-year follow-up from a randomized, controlled study | Q85023204 | ||
| Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward | Q87014509 | ||
| Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy | Q87071200 | ||
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 211-225 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Clinical transplants | Q27709761 |
| P1476 | title | Modernization of Chronic Allograft Injury Research: Better Biomarkers, Better Studies, Better Outcomes | |
| P478 | volume | 31 |
Search more.